A double blind, placebo controlled study of E5564, A Lipid A Antagonist administered by twice daily intravenous infusions in patients with severe sepsis

A multi-center randomized, double blind, parallel group-placebo controlled trial on efficacy and safety of activated Recombinant Factor VII (rFVIIa/NovoSeven ) in the treatment of bleeding in patients following hematopoietic stem cell transplantation

A Safety evaluation of Xigris (Drotecogin alfa activated) in Hematopoietic Stem Cell Transplant Patients with Severe Sepsis